Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.50 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24876971 | 0.91 | CTSK (0.47) | CTSKCTSSMAPTATMPPARA | |
| SCHEMBL16565003 | 0.87 | NPC1 (0.44) | CTSKCTSSMAPTATM | |
| SCHEMBL29465735 | 0.86 | CTSK (0.52) | CTSKCTSSMAPTATMGABRB1 | |
| SCHEMBL5460811 | 0.86 | CTSK (0.52) | CTSKCTSSMAPTATMGABRB1 | |
| SCHEMBL717324 | 0.86 | CTSK (0.52) | CTSKCTSSMAPTATMGABRB1 | |
| SCHEMBL1784108 | 0.86 | CTSK (0.52) | CTSKCTSSMAPTATMGABRB1 | |
| SCHEMBL4583120 | 0.85 | CTSK (0.53) | CTSKCTSSMAPTATMGABRB1 | |
| SCHEMBL28464584 | 0.85 | CTSK (0.53) | CTSKCTSSMAPTATMGABRB1 | |
| SCHEMBL56596 | 0.85 | CTSK (0.53) | CTSKCTSSMAPTATMGABRB1 | |
| SCHEMBL56698 | 0.85 | CTSK (0.53) | CTSKCTSSMAPTATMGABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023283639-A1 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | LUNG THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | CTSK 3111/4885CTSS 3002/4885MAPT 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.